Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity
Open Access
- 14 February 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (3) , 305-311
Abstract
Ibrutinib is a covalent BTK inhibitor that is approved for several indications in oncology. Ibrutinib possesses significant off-target activities toward many kinases, often leading to adverse events in patients. While there have been robust medicinal chemistry efforts leading to more selective second-generation BTK inhibitors, there remains a need for new strategies to rapidly improve the selectivity of kinase inhibitors. An analysis of PDB data revealed that ibrutinib binds BTK in dihedral conformations that are orthogonal of ibrutinib's predicted low energy conformational range. Synthesis of a series of analogues with ground state conformations shifted toward orthogonality led to the discovery of an analogue with two incorporated ortho-methyl groups that possessed markedly increased BTK selectivity. This work suggests that conformational control about a prospective atropisomeric axis represents a strategy to rapidly program a compound's selectivity toward a given target.Keywords
Funding Information
- National Institute of General Medical Sciences (R35GM124637)
This publication has 36 references indexed in Scilit:
- Profound Methyl Effects in Drug Discovery and a Call for New C-H Methylation ReactionsAngewandte Chemie International Edition, 2013
- Assessing Atropisomer Axial Chirality in Drug Discovery and DevelopmentJournal of Medicinal Chemistry, 2011
- The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug CandidatesJournal of Medicinal Chemistry, 2011
- The Src, Syk, and Tec family kinases: Distinct types of molecular switchesCellular Signalling, 2010
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- B-cell-depletion therapy in SLE—what are the current prospects for its acceptance?Nature Reviews Rheumatology, 2009
- Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectoriesProceedings of the National Academy of Sciences, 2009
- Non‐Biaryl Atropisomers: New Classes of Chiral Reagents, Auxiliaries and Ligands?2003
- Signaling network of the Btk family kinasesOncogene, 2000